Evidence map›Paper›PMID 40016256›Full record

ArticleScientific reports2025

Repurposing of apoptotic inducer drugs against Mycobacterium tuberculosis.

Kudakwashe Nyambo, Vivette Soko, Kudzanai Ian Tapfuma, Bongani Motaung, Francis Adu-Amankwaah, Lauren Julius, Ashwil Klein, Marshall Keyster, Lucinda Baatjies, Liezel Smith and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kudakwashe Nyambo *DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Vivette Soko *DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Kudzanai Ian TapfumaDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Bongani MotaungDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Francis Adu-AmankwaahDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Lauren JuliusDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Ashwil KleinDepartment of Biotechnology, University of Western Cape, Bellville, Cape Town, South Africa.
Marshall KeysterDepartment of Biotechnology, University of Western Cape, Bellville, Cape Town, South Africa.
Lucinda BaatjiesDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Liezel SmithDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
Krishna Kuben GovenderDepartment of Chemical Sciences, Doornfontein Campus, University of Johannesburg, P. O. Box 17011, Johannesburg, 2028, South Africa.
Mkhuseli NgxandeComputer Science Division, Department of Mathematical Sciences, Faculty of Science, University of Stellenbosch, Matieland, South Africa.
Andre G LoxtonDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa. gl2@sun.ac.za.
Vuyo MavumengwanaDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa. vuyom@sun.ac.za.

Funding

National Research Fund [Postdoctoral GRANT PSTD23041794183]National Research Fund, South Africa Postdoctoral GRANT PSTD23041794183]
6 · The paper itself

Abstract

Computational approaches complement traditional in-vitro or in-vivo assays, significantly accelerating the drug discovery process by increasing the probability of identifying promising lead compounds. In this study, the apoptotic compounds were assessed for antimycobacterial activity and immunomodulatory potential in infected THP-1 macrophage cells. The antimycobacterial activity of the apoptotic compounds was evaluated using the minimum inhibitory concentration (MIC) assay. The immunomodulatory potential of the apoptotic compounds was determined on mycobacterial-infected THP-1 and non-infected THP-1 macrophage cells. The potential binding dynamics of the compounds against InhA were predicted using molecular docking, molecular dynamics, and MM-GBSA binding free energies. The in-vitro MIC assay showed that cepharanthine (CEP) had the highest antimycobacterial activity against Mycobacterium smegmatis mc

Indexed as

Antitubercular AgentsApoptosisDrug RepositioningMycobacterium tuberculosisBacterial ProteinsHumansMacrophagesMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationTHP-1 CellsAntitubercular AgentsBacterial ProteinsCytokine profilingDrug repurposingHost-directed therapyMolecular dynamics simulationTuberculosis

Identifiers

PMID40016256
PMCPMC11868625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.